00da descexport-xml.xsl*:*20standardxsltdb:"NGC"10EvaluationManagementRisk AssessmentScreeningTechnology AssessmentTreatmentNGC10014Overall survivalDisease-free survivalQuality of lifeToxicityCost-effectivenessPreoperative carcinoembryonic antigen (CEA) testing for staging and surgical treatment planningPostoperative CEA testing to detect possible metastatic diseaseCEA testing to monitor metastatic colorectal cancer during systemic therapyCA 19-9 testing for monitoring response to therapyCEA as a screening test for colorectal cancerCEA testing to determine whether to treat patients with colorectal cancer with adjuvant therapyUse of CA 19-9 for screening, diagnosis, staging, surveillance, or monitoring treatment of patients with colorectal cancerUse of flow-cytometrically derived DNA ploidy (DNA index) or DNA flow cytometric proliferation analysis (%S phase) to determine prognosis of early stage colorectal cancerUse of p53 expression or mutation for screening, diagnosis, staging, surveillance, or monitoring treatment of patients with colorectal cancerUse of the rasoncogene for screening, diagnosis, staging, surveillance, or monitoring treatment of patients with colorectal cancerUse of thymidine synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) tests for screening, prognosis, predicting response to therapy, or monitoring response to therapy of patients with colorectal cancerMicrosatellite instability (MSI) ascertained by polymerase chain reaction (PCR) to determine the prognosis of operable colorectal cancer or to predict the effectiveness of fluorouracil (FU) adjuvant chemotherapyAssaying for loss of heterozygosity (LOH) on the long arm of chromosome 18 (18q) or deleted in colon cancer (DCC) protein determination by immunohistochemistry to determine the prognosis of operable colorectal cancer, or to predict response to therapyUse of CA 19-9 as a screening test for pancreatic cancerUse of CA 19-9 testing alone for determining operability or the results of operability in pancreatic cancer and for providing definitive evidence of disease recurrenceColon and Rectal SurgeryFamily PracticeGastroenterologyInternal MedicineOncologyRadiation OncologySurgeryPatients with colorectal cancer or pancreatic cancerASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10014NGC10015Advanced Practice NursesAllied Health PersonnelClinical Laboratory PersonnelDietitiansHealth Care ProvidersHealth PlansNursesPatientsPhysician AssistantsPhysiciansSocial WorkersMorbidity (including cardiovascular and cerebrovascular events) and mortality among end-stage renal disease patients on hemodialysisLongevityIndicators of hemodialysis adequacyFrequency of intradialytic symptomsFrequency of hospitalizationIntermediate outcomes (e.g. clearance and filtration measures)Adverse events due to treatmentQuality of lifePatient education about kidney failure and options for its treatmentEstimation of kidney function (glomerular filtration rate)Optimal timing of initiation of dialysisMonitoring of hemodialysis dose (including formal urea kinetic modeling)Assessment of hemodialysis adequacy (including blood urea nitrogen [BUN])Control of fluid volume and blood pressurePreservation of residual kidney function (RKF) (e.g., use of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, avoidance of nephrotoxic insults)Quality improvement programsFamily PracticeInternal MedicineNephrologyPediatricsAdult and pediatric patients on hemodialysisNKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2006.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10015ManagementTreatmentNGC10016Advanced Practice NursesAllied Health PersonnelClinical Laboratory PersonnelHealth Care ProvidersHealth PlansNursesPatientsPhysician AssistantsPhysiciansSocial WorkersMorbidity (including cardiovascular and cerebrovascular events) and mortality among end-stage renal disease patients on hemodialysisSurvivalIndicators of peritoneal dialysis (PD) adequacyPatient adherence to PD prescriptionHospitalizationTechnique survivalNutritionGrowth (pediatrics)Cognitive function (pediatrics)Blood pressure/hypertensionLeft ventricular hypertrophy (LVH)Quality of LifePatient education about kidney failure and options for its treatmentEstimation of kidney function by estimation of glomerular filtration rate (GFR)Optimal timing of initiation of dialysisMeasures of peritoneal dialysis dose and total solute clearancePreservation of residual kidney function, including use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) and avoiding insults to residual kidney function (RKF)Maintenance of euvolemia through monthly monitoring and therapies to optimize extracellular water, blood volume, and blood pressureEstablishment of quality improvement programsFamily PracticeInternal MedicineNephrologyPediatricsAdult and pediatric patients with end-stage renal disease who receive peritoneal dialysis (PD) treatment, primarily patients on continuous ambulatory PD (CAPD)NKF-KDOQI clinical practice guidelines for peritoneal dialysis adequacy: update 2006.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10016EvaluationManagementTreatmentNGC10017Advanced Practice NursesAllied Health PersonnelClinical Laboratory PersonnelDietitiansHealth Care ProvidersHealth PlansNursesPatientsPhysician AssistantsPhysiciansSocial WorkersVascular access-related morbidityMaturation and function of new arteriovenous fistula (AVF)Change in approach to access placementInfection ratesInfection clearing ratesReinfection ratesInfection-free timeAccess survivalMaintenance of access patency/functionBlood flow achievedSensitivity and specificity of tests for periodic monitoring of accessRe-establishment of patency/function in malfunctioning catheterHospitalizationCosts associated with the maintenance of access patencyPatient education on modalities of kidney replacement therapy (KRT) and monitoring of accessesPatient evaluation prior to placement of permanent hemodialysis (HD) access, including history and physical exam, duplex ultrasound, and central vein evaluationStructured approach to selection of the type of hemodialysis access (fistula, graft, or peritoneal dialysis catheter)Structured approach to selection of the location of hemodialysis access Fistula: wrist, elbow, or transposed brachial basilica vein Arteriovenous graft (AVG): forearm loop, upper arm, chest wall Catheters and port catheter systems: right internal jugular vein or secondary locationsStructured approach to selection of the location of hemodialysis access Fistula: wrist, elbow, or transposed brachial basilica veinArteriovenous graft (AVG): forearm loop, upper arm, chest wallCatheters and port catheter systems: right internal jugular vein or secondary locationsPlacement of functional permanent access prior to initiation of dialysis therapyUse of aseptic technique and appropriate cannulation methods of fistulae and graftsOptimal timing of fistula and graft cannulationMonitoring of fistula maturationUse of infection control measures for all HD cathetersAn organized monitoring/surveillance approach to detect access dysfunction Physical examination Surveillance of grafts and fistulae Referral for evaluation (diagnostic) and treatmentAn organized monitoring/surveillance approach to detect access dysfunction Physical examinationSurveillance of grafts and fistulaeReferral for evaluation (diagnostic) and treatmentTimely evaluation and treatment of fistula complications Assessment of persistent swelling, delays in maturation, inadequate blood flow, venous stenosis, thrombosis, aneurysm, ischemia, infection Treatment of stenosis with percutaneous angioplasty (PTA) or surgical revision Treatment of thrombosis with thrombectomy Referral of patients with an arteriovenous fistula (AVF) with ischemia to a vascular access surgeon Treatment of infections with antibiotics and, for extensive infection, resection of the infected graft materialTimely evaluation and treatment of fistula complications Assessment of persistent swelling, delays in maturation, inadequate blood flow, venous stenosis, thrombosis, aneurysm, ischemia, infectionTreatment of stenosis with percutaneous angioplasty (PTA) or surgical revisionTreatment of thrombosis with thrombectomyReferral of patients with an arteriovenous fistula (AVF) with ischemia to a vascular access surgeonTreatment of infections with antibiotics and, for extensive infection, resection of the infected graft materialManagement and treatment of AVG complications Assessment of extremity edema, risks for graft rupture, severe degenerative changes, pseudoaneurysm, stenosis, thrombosis, infection Treatment of AVGs with severe degenerative changes or pseudoaneurysm with revision/repair Treatment of stenosis without thrombosis with angioplasty or surgical revision Treatment of thrombosis and associated stenosis with percutaneous thrombectomy with angioplasty or surgical thrombectomy with AVG revision Treatment of infection with antibiotics, and for extensive infection, resection of the infected graft materialManagement and treatment of AVG complications Assessment of extremity edema, risks for graft rupture, severe degenerative changes, pseudoaneurysm, stenosis, thrombosis, infectionTreatment of AVGs with severe degenerative changes or pseudoaneurysm with revision/repairTreatment of stenosis without thrombosis with angioplasty or surgical revisionTreatment of thrombosis and associated stenosis with percutaneous thrombectomy with angioplasty or surgical thrombectomy with AVG revisionTreatment of infection with antibiotics, and for extensive infection, resection of the infected graft materialEvaluation of dysfunctional catheters and ports to facilitate prevention and early treatment Treatment of dysfunctional catheters and ports with repositioning, thrombolytics, or catheter exchange with sheath disruption Treatment infected HD catheter or port with antibiotic(s)Evaluation of dysfunctional catheters and ports to facilitate prevention and early treatment Treatment of dysfunctional catheters and ports with repositioning, thrombolytics, or catheter exchange with sheath disruptionTreatment infected HD catheter or port with antibiotic(s)Use of continuous quality improvement (CQI) to monitor clinical outcome goalsFamily PracticeInternal MedicineNephrologyPediatricsAdult and pediatric patients with end-stage renal disease who receive hemodialysis treatmentNKF-KDOQI clinical practice guidelines for vascular access: update 2006.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10017EvaluationManagementTreatmentNGC10018Erectile function as measured by the International Index of Erectile Function (IIEF)Intercourse satisfactionAbility to have intercourseReturn to normal functionAdverse eventsIdentification of comorbidities and psychosexual dysfunctions through sexual, medical, and psychosocial historyLaboratory testsFocused physical examinationProstate-specific antigen measurementRectal examinationAdditional testing, such as testosterone level measurement, vascular and/or neurological assessment and monitoring of nocturnal erectionsEducate patients regarding treatment options and associated risks and benefitsManage risk factors for erectile dysfunction (e.g., lifestyle modifications to prevent or reverse erectile dysfunction [ED])Consider comorbidities when managing patients with ED (e.g., provide appropriate management of patients with ED in the presence of cardiovascular disease)Pharmacologic therapy Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) Alprostadil intra-urethral suppositories Intracavernous injection with alprostadil, papaverine, or phentolamine or combinationsPharmacologic therapy Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil)Alprostadil intra-urethral suppositoriesIntracavernous injection with alprostadil, papaverine, or phentolamine or combinationsVacuum constriction devicesSurgery Penile prosthesis implantation with preoperative administration of antibiotics Vascular surgery (penile arterial reconstructive surgery)Surgery Penile prosthesis implantation with preoperative administration of antibioticsVascular surgery (penile arterial reconstructive surgery)Periodic follow-up of efficacy, side effects, and change in health statusFamily PracticeInternal MedicineSurgeryUrologyMen who have erectile dysfunction after a well-established period of normal erectile function, whose erectile dysfunction is primarily organic rather than psychological in nature, and who have no evidence of hypogonadism or hyperprolactinemia(1) The management of erectile dysfunction: an update. (2) 2006 addendum.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10018NGC10019Advanced Practice NursesHealth Care ProvidersNursesPhysician AssistantsPhysiciansRespiratory Care PractitionersSocial WorkersTo integrate environmental management of asthma into pediatric health careTo educate health care professionals on how to advise families about environmental interventions that can reduce or eliminate triggers for children who are already diagnosed with asthmaTo guide primary care providers to consider environmental factors that may affect their patients' asthma. In some cases triggers may be more readily apparent than othersAsthma associated morbidityReduction or elimination of triggers for children who are already diagnosed with asthmaAdministration of environmental history Environmental History Form for Pediatric Asthma PatientAdministration of environmental history Environmental History Form for Pediatric Asthma PatientAllergy testing if indicatedReferral to asthma specialist if indicatedCounseling of patient and patient's family on controlling exposures that trigger child's asthma: Dust mites Animal allergens Cockroach allergen Mold/mildew Tobacco smoke Air pollutionCounseling of patient and patient's family on controlling exposures that trigger child's asthma: Dust mitesAnimal allergensCockroach allergenMold/mildewTobacco smokeAir pollutionFollow-up visitsAllergy and ImmunologyEmergency MedicineFamily PracticeInternal MedicineNursingPediatricsPulmonary MedicineChildren 0 to 18 years of age already diagnosed with asthmaEnvironmental management of pediatric asthma. Guidelines for health care providers.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10019DiagnosisEvaluationManagementRehabilitationTreatmentNGC10043Allied Health PersonnelDentistsDietitiansHealth Care ProvidersNursesPhysiciansSpeech-Language PathologistsIncidence of head and neck cancerRecurrence rateSurvival rateQuality of lifeSmoking and chewing tobacco cessationAlcohol limitationAlcohol counseling servicesDietary counselingPrevention leaflet availabilityFine needle aspirationEndoscopyChest x-rayComputed tomography (CT) scanMagnetic resonance imaging (MRI)Fluorodeoxy glucose positron emission tomography (FDG-PET)Tumor-node-metastasis (TNM) stagingHuman papillomavirus (HPV) subtypingProliferation indices/molecular markersSurgery Radical neck dissection Modified radical neck dissection Tumor resection Endoscopic laser excision Reconstructive surgerySurgery Radical neck dissectionModified radical neck dissectionTumor resectionEndoscopic laser excisionReconstructive surgeryExternal-beam radiotherapy Conventional fractionation Hypofractionation Hyperfractionation Accelerated fractionation Decreased total dose and very accelerated fractionation Modified fractionation and chemotherapyExternal-beam radiotherapy Conventional fractionationHypofractionationHyperfractionationAccelerated fractionationDecreased total dose and very accelerated fractionationModified fractionation and chemotherapyBrachytherapyPrevention of radiation-induced side effects Benzydamine oral rinse to prevent mucositis Pilocarpine for xerostomia Amifostine for xerostomia (not recommended)Prevention of radiation-induced side effects Benzydamine oral rinse to prevent mucositisPilocarpine for xerostomiaAmifostine for xerostomia (not recommended)Adjuvant radiotherapy following surgeryChemotherapy in combination with surgery (neoadjuvant and adjuvant chemotherapy are not recommended)Radiotherapy and concurrent chemotherapy with cisplatin, cisplatin/5-fluorouracil (5FU), cisplatin/5FU/docetaxelRadiotherapy and concurrent monoclonal antibody therapy with cetuximabSalvage surgeryRe-irradiationBrachytherapyChemotherapy with methotrexate, cisplatin, cisplatin/5FU, or cisplatin/5FU/cytarabineRadiotherapySurgeryOral and dental rehabilitationSpeech and language therapyNutrition supportPatient supportFollow-upDentistryFamily PracticeInternal MedicineNursingNutritionOncologyOtolaryngologyPhysical Medicine and RehabilitationPlastic SurgeryRadiation OncologySpeech-Language PathologySurgeryPatients at risk for or who have the following head and neck cancers: laryngeal cancer, hypopharyngeal cancer, oropharyngeal cancer, or oral cavity cancerDiagnosis and management of head and neck cancer. A national clinical guideline.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10043Assessment of Therapeutic EffectivenessManagementNGC10153To provide guidelines for the therapeutic use of androgens in womenTo outline the areas of future researchAccuracy (sensitivity, specificity) of existing methods of testosterone measurementResponse to androgen therapy in terms of bone mineral density, cognitive function, quality of life, sexual function, mood, cardiovascular function, body composition, and muscle strength and function in women with androgen deficiencySafety profile of androgen therapyEndocrinologyWomen with androgen deficiencyAndrogen therapy in women: an Endocrine Society clinical practice guideline.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10153Assessment of Therapeutic EffectivenessManagementTreatmentNGC10158To evaluate the optimal surgical management of ductal carcinoma in situ (DCIS) of the breastTo evaluate whether breast irradiation should be offered to women with DCIS, following breast-conserving surgery (defined as excision of the tumour with microscopically clear resection margins)To evaluate whether there are patients who could be spared breast irradiation post–breast-conserving surgery for DCISTo evaluate the role of tamoxifen in the management of DCISOverall survivalDisease-free survivalLocal recurrenceBreast conservationDistant recurrenceToxicityQuality of lifeTotal mastectomyBreast-conserving surgery (lumpectomy)Radiotherapy following breast-conserving surgeryTamoxifen and radiotherapy versus radiotherapy aloneOncologyRadiation OncologySurgeryWomen with ductal carcinoma in situ (DCIS) of the breastManagement of ductal carcinoma in situ of the breast: a clinical practice guideline.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10158NGC10160Advanced Practice NursesNursesPhysiciansTo prevent catheter-related intraluminal thrombosis and local or systemic catheter-related infection, minimize the need to replace devices, and enhance quality of life among children and adults with cancer by assessing: Whether central venous access devices (CVAD) should be locked with heparin or salineWhat volume and strength of solution should be used to lock CVADsHow frequently CVADs should be lockedWhat type of catheter should be usedTo evaluate, in patients who require systemic therapy for cancer, the indicators (e.g., functional or quantitative neutropenia, age, diagnosis, therapy, immune status, or patient convenience) that have an impact on the decision to insert a central venous access deviceCatheter-related thrombosisCatheter-related infectionRates of removal due to infection or occlusionQuality of lifeOncologyAdult and pediatric patients requiring central venous access devices for cancer treatmentManaging central venous access devices in cancer patients: a clinical practice guideline.http://www.guidelines.gov/summary/summary.aspx?ss=15&doc_id=10160305